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Background: Hydrogen sulfide (H2S) produces a protective effect against myocardial ischemia and reperfusion 
injury. Sevoflurane, which is used for anesthesia in cardiac problem patients, also has a protective effect. This study is 
designed to reveal the effects of H2S under sevoflurane using rat hearts.
Methods: The hearts were Langendorff-perfused, subjected to 30 minutes ischemia and 60 minutes reperfusion. 
Group I was a control group. The other groups were pretreated for 15 minutes before ischemia as follows: 1.6% 
sevoflurane for group S; 18.5 μM H2S S for group H; and 1.6 % sevoflurane and 18.5 μM H2S simultaneously for group 
HS. Hemodynamics and the infarct size were measured.
Results: Group HS presented depressed hemodynamics during pretreatment. LV function in group HS achieved 
better recovery than group I after reperfusion. The infarct size of groups S, H and HS was smaller than group I, while 
there were no differences between groups S, H and HS.
Conclusions: Exogenous H2S did not enhance the preconditioning effects of sevoflurane. Rather, the results suggest 
that H2S under sevoflurane might depress hemodynamics. (Korean J Anesthesiol 2012; 62: 461-467)
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Introduction
In administering anesthetics to high cardiac risk patients for 
surgery, the primary purpose is to maintain a cardiac reservoir. 
Of the many attempts to achieve this during anesthesia, a 
great deal of attention has been paid to the powerful defense 
mechanism, ischemic preconditioning that results from short 
repetitive myocardial ischemia. However, since there are 
difficulties in utilizing ischemic preconditioning during surgery 
[1,2], considerable research has been undertaken in the pursuit 
of a pharmacological solution with effects that are similar 
to ischemic preconditioning. Several substances, including 
halogenated inhalation anesthetics, have been found to cause 
such pharmacological preconditioning [3]. Sevoflurane is a 
halogenated inhalation anesthetic which has a pharmacological 
preconditioning effect and so is often used as a general anesthetic 462 www.ekja.org
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for patients with cardiac diseases [4].
Hydrogen sulfide (H2S) is thought to be a gasotransmitter 
that is naturally produced in small amounts in the human 
body such as nitric oxide (NO) and carbon monoxide (CO) 
and has many biological functions [5]. H2S is synthesized from 
L-cysteine through the action of cystathionine γ-lyase in the 
myocardium, fibroblasts and the vascular smooth muscles, 
and is well distributed throughout the cardiovascular system. 
H2S reduces the contractility of the myocardium and acts as a 
vasodilator leading to the dilation of vascular smooth muscles 
[6]. Several animal-based studies have shown that externally 
administered H2S has the same effect as natural H2S in reducing 
damage from myocardial ischemia and reperfusions [7-12]. 
Its myocardial protective effects are regarded as similar to 
that of ischemic preconditioning; H2S has a unique action in 
vertebrates called ‘suspended animation-like state’ [13]. That 
is, H2S induces extremely low metabolism and low oxygen 
consumption status such as deep hypothermia, and can protect 
vital organs including the heart against ischemia and reper-
fusion injury [13-16]. 
It is thought that if H2S is administrated along with sevo-
flurane, it can provide another effect against myocardial damage 
from ischemia occurring due to surgery or the course of the 
disease, subsequently leading to the reduction of post-operative 
myocardial dysfunction in high-risk patients. However, H2S is 
not yet in clinical use because its mechanisms, pharmacological 
actions and interactions with other medications are not fully 
understood. Therefore, this study was conducted to examine 
the effects of H2S on isolated rat hearts that were treated with 
sevoflurane and to analyze what effects the H2S would exert on 
the myocardium.
Materials and Methods
The study protocol was approved and all procedures were 
performed in accordance with the guidelines recommended by 
the Institutional Animal Care and Use Committees.
Our study utilized an isolated rat heart model on a Langen-
dorff system (Radnoti Co., Colorado Springs, Colorado, USA). 
The hearts were taken from 52 male Spraque-Dawley white rats 
weighing between 250-350 g, and were divided into 4 groups 
by using a block randomization.
Phenobarbital 100 mg/kg was injected into the abdominal 
cavity of each rat and the cessation of voluntary movement 
was ascertained. Once the rat was completely anesthetized, 
1,000 IU heparin was injected into the abdominal cavity. 
Before spontaneous respiration ceased, a tracheotomy was 
performed and a 16-G catheter was inserted and attached to 
an animal respirator (SN-480-7, Shinano Co., Nagano, Japan). 
Mechanical ventilation was initiated at 50 breaths/min, with 
3-4 ml tidal volume using 95% oxygen-5% carbon dioxide. The 
sternum was incised and the heart was exposed. The heart was 
then extracted and immediately placed in iced perfusate to 
stop movement and prevent damage to the myocardium. The 
Langendorff system’s perfusate cannula was inserted into the 
aorta of the isolated heart, with the tip positioned immediately 
above the aortic valve through which the perfusate was entered 
into the coronary artery. The perfusate used was a modified 
Kreb’s solution (NaCl 118.0 mM, KCl 4.7 mM, CaCl2 1.9 mM, 
MgSO4 1.2 mM, NaHCO3 25.0 mM, KH2PO4 1.2 mM, Glucose 
10.1 mM, Na-EDTA 0.5 mM). The perfusate was maintained 
at 37 ± 0.2
oC using a heated circulator with an automated 
temperature control (CW-10G, Jeio Tech Co. Seoul, Korea) 
and entered the Langendorff system’s oxygenator through a 
perfusate pump (Masterflex, Cole-Parmer Instrument Co., 
USA). The perfusate’s height was maintained at 75 cm, and 
the pressure of the perfusate entering the coronary artery was 
maintained at 55 mmHg. The perfusate’s pH was maintained at 
7.4 ± 0.02 by setting the oxygenator at 95% oxygen-5% carbon 
dioxide at 3 L/min. In order to continuously measure hemo-
dynamic parameters, a latex balloon filled with saline was 
inserted through the left mitral valve into the left ventricle, and 
a stainless steel conduit was used to connect a pressure sensor 
(Ohmeda P23XL transducer, Ohmeda, Oxnard, CA, USA) to an 
MP-100 system (Biopac
Ⓡ system Inc., CA, USA) and an MP-
100 manager program, Acknowledge version 3.8.2 (Biopac
Ⓡ
system Inc., CA, USA). The other cannula was introduced 
through the coronary sinus via the right atrium for measuring 
the coronary effluent rates. Then, after stabilization, the balloon 
was controlled to obtain a left ventricular end diastolic pressure 
of around 10 mmHg before observation.
All hearts in the 4 groups were maintained on the Langen-
dorff system, allowed to stabilize, given the initial treatment for 
15 minutes, underwent artificially induced global ischemia for 
30 minutes, and then underwent reperfusion for 60 minutes. 
Initial treatment in group I (ischemia) was simply to maintain 
coronary flow. Group S (sevoflurane) hearts were treated with 
sevoflurane at 1.6 vol% through the oxygenator using a Sevotec 
5 vaporizer (Datex-Ohmeda, Tewksbury, MA, USA), group H 
(H2S) hearts were treated with the perfusate containing 100 μM 
sodium hydrosulfide corresponding to 18.5 μM H2S and group 
HS (H2S and sevoflurane) hearts were treated with the perfusate 
containing 18.5 μM H2S as well as with 1.6 vol% sevoflurane 
during the pre-treatment period (Fig. 1). Measurements for 
statistical analysis were taken directly after stabilization and 
after pre-treatment as well as 5, 30 and 60 minutes after initi-
ation of reperfusion. Variables recorded for analysis were the left 
ventricular end systolic pressure (LVESP), left ventricular end 
diastolic pressure (LVEDP), maximum difference of ventricular 
pressure (dP/dtmax) and heart rate (HR), as well as coronary 463 www.ekja.org
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effluent flow rate (CEFR).
After reperfusion was completed, the heart was immediately 
frozen at -20
oC to prevent damage to the muscles. All of the 
ventricular muscles were cut into 2 mm along the short axis of 
heart, and the slices were stained with triphenyl tetrazolium in 
a water bath of 37
oC for 10-15 minutes. The staining agent was 
created by dissolving triphenyl tetrazolium salt (2,3,5-Triphenyl 
tetrazolium chloride: C19H15ClN4) to 1% in a buffer solution of 
monosodium phosphate (NaH2PO4) and disodium phosphate 
(Na2HPO4) with a pH of 7.4. Once staining was complete, each 
muscle segment was fixed for 20 minutes in a 10% formaldehyde 
solution. The samples were then made into a uniform thickness 
with 2 thick glasses and 2 mm thick shims, then examined using 
a UTHSCSA Image Tool, version 3.0 (S. Brent Dove, University 
of Texas Health Science Center in San Antonio, Texas, USA). The 
volumes corresponded to the damaged tissues and all of the 
ventricles were measured and the infarct size was calculated as 
a ratio (%) of the sum of damaged volumes to whole ventricle.
All statistical analyses were performed using SigmaStat for 
Windows, version 3.0.1a (Systat software Inc., San Jose, CA, 
USA). Friedman repeated measures analysis of variance on 
ranks or Kruskal-Wallis one-way analysis of variance on ranks 
was used, depending on the nature of the data. When the 
results were significant, multiple comparisons were made with 
the Dunn’s Method. A P value of less than 0.05 was considered 
statistically significant.
Results
52 rat hearts were extracted and randomly divided into 4 
groups. Rats in which technical failures occurred or adequate 
heart function did not continue through to stabilization 
were excluded. In total, group I contained 10 hearts, group S 
contained 13, group H contained 10, and group HS contained 
12.
Hemodynamic variables and CEFR
In group HS, LVESP was lower immediately after pretreat-
ment than after stabilization (P < 0.001, Fig. 2). 5 minutes after 
reperfusion, LVESP was higher in group H than in groups I and 
S (P < 0.001). In group HS, the pressure was lower than in group 
H, but did not show depressed LVESP as in group S. During the 
remainder of the reperfusion period, the pressure decreased 
gradually over time. However, the pressure was higher in groups 
H and HS than in group I (P < 0.001).
During the reperfusion period, LVEDP increased initially, 
then decreased gradually in all groups (Fig. 3). But 30 minutes 
after reperfusion, the pressure was lower in group S than in 
groups I and H (P < 0.001). Then, 60 minutes after reperfusion, 
the pressure was further decreased, and the differences bet-
Fig. 1. Experimental protocol. After stabilization, each group was subjected to 30 minutes of global ischemia and 60 minutes of reperfusion. 
Before global ischemia, a 15 minute pre-treatment period was conducted and specific agents were applied to each group as follows: perfusate 
and mixed gas (95% O2 + 5% CO2) only for group I; mixed gas with 1.6% sevoflurane and perfusate without H2S for group S; 18.5 μM H2S mixed 
perfusate and mixed gas for group H; 1.6% sevoflurane and 18.5 μM H2S for group HS. Hemodyamic variables were measured after stabilization, 
after pre-treatment and 5, 30, 60 minutes after reperfusion started (Arrows). After all processes were completed, triphenyl tetrazolium staining 
was performed to calculate infarct size.
Fig. 2. Left ventricular end systolic pressure. Group HS showed lower 
systolic pressure after pre-treatment than those after stabilization. 
Groups H and HS showed mostly higher pressures during the 
reperfusion period than groups I and S. St: after stabilization, 
Tx: pretreatment, R5: reperfusion 5 minutes, R30: reperfusion 30 
minutes, R60: reperfusion 60 minutes. P < 0.05 is remarked as 
follows: * vs. after stabilization in the same group. 
† vs. Group I, 
‡ vs. 
Group S, 
§ vs. Group H at the same measurement time.464 www.ekja.org
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ween the groups disappeared. 
All groups showed reduced HR during the reperfusion 
period. However, the rate was relatively higher in group S than 
in groups H and HS (P < 0.001, Fig. 4). 
dP/dtmax in group S abruptly decreased 5 minutes after 
reperfusion, similarly to group I (P < 0.001, Fig. 5). The decre-
ment of dP/dtmax was also observed in groups H and HS, and 
group S showed a significantly greater drop than other groups. 
30 and 60 minutes after reperfusion, dP/dtmax in all groups 
maintained a lowered value compared to the values measured 
after stabilization. In all groups, CEFR showed a gradual 
reduction during the reperfusion period (Fig. 6). However, in 
group S, the rate was generally higher than in the other groups 
throughout the reperfusion period (P < 0.001).
Infarct Size (Fig. 7)
Infarct size was significantly smaller in groups S, H and HS 
than in group I (P = 0.001). There were no significant differences 
between groups S, H and HS.
Fig. 3. Left ventricular diastolic pressure. During the reperfusion 
period, diastolic pressure in all groups initially increased, and then 
progressively decreased over time. In group H, diastolic pressure 
was sustained at a high rate until 30 minutes after reperfusion and 
then decreased toward the value of that after stabilization. Groups 
S and HS showed similar patterns in pressure changes. St: after 
stabilization, Tx: pretreatment, R5: reperfusion 5 minutes, R30: 
reperfusion 30 minutes, R60: reperfusion 60 minutes. P < 0.05 is 
remarked as follows: * vs. after stabilization and/or pretreatment in 
the same group, 
† vs. groups I and H at the same measurement time.
Fig. 4. Heart rate. Heart rates during the reperfusion period in all 
groups were lower than those prior to ischemia. Heart rates in 
groups H and HS were mostly lower than those in group S during 
the reperfusion period. St: after stabilization, Tx : pretreatment, 
R5: reperfusion 5 minutes, R30: reperfusion 30 minutes, R60: 
reperfusion 60 minutes. P < 0.05 is remarked as follows: * vs. after 
stabilization in the same group, 
† vs. groups I, 
‡ vs. group S at the 
same measurement time.
Fig. 6. Coronoary effluent flows measured in rate. During the reper-
fusion period, coronary effluent flow rates of all groups decreased 
with time. Primarily, group S showed higher rates than groups I, H 
and HS. St: after stabilization, Tx: pretreatment, R5: reperfusion 5 
minutes, R30: reperfusion 30 minutes, R60: reperfusion 60 minutes. 
P < 0.05 is remarked as follows: * vs. after stabilization in the same 
group. At the same measuring time, 
† vs. groups I, 
‡ vs. group S at 
the same measurement time.
Fig. 5. Maximum rate of change of left ventricular pressure (dP/
dt max). 5 minutes after reperfusion, dP/dt max in groups I and S 
decreased rapidly. During the rest of reperfusion, dP/dt max of all 
groups remained low. St: after stabilization, Tx: pretreatment, R5: 
reperfusion 5 minutes, R30: reperfusion 30 minutes, R60: reperfusion 
60 minutes. P < 0.05 is remarked as follows: * vs. after stabilization in 
the same group.465 www.ekja.org
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Discussion
After ischemic preconditioning was introduced to prevent 
damage due to myocardial ischemia and reperfusion that 
occurs because of surgical manipulation or other causes [17], 
considerable research has been actively pursued and many 
clinical trials for the use of ischemic preconditioning are being 
performed [2]. Because pretreatment by short and repeated 
ischemia and reperfusion is highly dangerous [1], recent 
studies have focused on chemical pretreatments, including 
halogenated inhalation anesthetics and adenosine [3,4]. Among 
these agents, pharmacological preconditioning by inhalation 
anesthetics is mainly mediated through activation of protein 
kinase C (PKC) and ATP-sensitive potassium channels [18]. In 
addition, it has been demonstrated that inhalation anesthetics 
control the activity of nitric oxide synthase (NOS), which 
plays an important role in reducing ischemic damage and in 
maintaining CEFR [19]. Sevoflurane is a newly synthesized 
halogenated inhalation anesthetic and its pharmacological 
preconditioning effect is well known [20,21].
Our study utilized 1.6 vol% sevoflurane, which is significantly 
less than the 2.4%, and this corresponds to 1 MAC in rats. In our 
previous study, it was found that a 1.6 vol% sevoflurane, which 
is short of 1 MAC, had a protective effect, where a concent-
ration higher than 1.6 vol% showed the same protective effect 
and instead reduced myocardial function [22]. Therefore, we 
chose to use 1.6 vol% sevoflurane concentration in order to 
prevent myocardial depression induced by sevoflurane and we 
found that the sevoflurane-pretreated hearts had less reduced 
function than group I. In addition, hearts treated with 1.6 vol% 
sevoflurane before ischemia had smaller infarct size compared 
to those in group I and so proved to have a pharmacological 
pretreatment effect. From a hemodynamic perspective, hearts 
that had been treated with sevoflurane showed a lower LVEDP, 
a higher HR and a higher CEFR during reperfusion than 
those in group I. These findings support the pharmacologic 
preconditioning effect of sevoflurane, as previously reported 
[20,21].
H2S is known to be involved in the regulation of the cardiova-
scular system and is accepted as a gasotransmitter, similar to 
NO and CO [5]. H2S was once thought to be toxic, but studies in 
mammals and human subjects have revealed that it is naturally 
produced in small amounts in the cardiovascular system. 
Since then, many studies have been focused on its function. In 
the cardiovascular system, H2S primarily functions to activate 
ATP-sensitive potassium channels, dilating blood vessels [6]. 
H2S has also been shown to suppress cytochrome c oxidase, 
which acts on the electron transfer system involved in cellular 
respiration. Thus, the suppression of oxidative phosphorylation 
results in extreme reduction of metabolism [13]. Moreover, 
externally administered H2S has an effect similar to ischemic 
pre  conditioning in reducing damage to the myocardium 
from ischemia and reperfusion and also in reducing infarct 
size. ATP-sensitive potassium channel activation appears to 
have some relevant effects [9,10]. Also, a previous study in 
rat cardiomyocytes has shown that H2S exerts a protective 
effect against ischemia through activation of PKC, including 
translocation of PKCα as well as PKCε, and PKCδ, which 
appears in the process of ischemic preconditioning, is slightly 
different in terms of PKC subtype. However, the relationships 
between H2S and PKC are not yet clear [11,23-25]. H2S is also 
believed to act as a buffer to increased oxygen consumption 
by regulating oxygen-consuming enzymes. In a study with 
mice, 150 ppm H2S gas suppressed metabolic rate by up to 
90%, protecting mice from lethal hypoxia, suggesting that in 
hypoxia, H2S can reduce the damage to myocardial tissue [14]. 
Beauchamp et al. [26] have reported that high concentrations of 
H2S are toxic and can cause respiratory failure and pulmonary 
edema because it suppresses cytochrome c oxidase, disabling 
mitochondrial electron transport systems. It has been suggested 
that, through the same mechanism, low concentrations of 
H2S can induce reversible suspended animation-like states in 
mam  mals [13,14]. Low concentrations of H2S, in the process 
of metabolizing oxygen to energy in cells, lowers the oxygen 
demand of cytochrome c oxidase, which in turn leads to the 
creation of fewer reactive oxygen species (ROSs) due to sudden 
oxygen cutoff or hypoxia and prevents ROS-related damage to 
cells during ischemia [14].
The physiological concentrations of H2S in rats have been 
reported to vary between 10 and 50 μM, and the maximum 
value has been shown to be 45.6 ± 14.2 μM [6]. The concent-
ration we used was 100 μM NaHS which corresponds to 18.5 
μM H2S. This concentration was within physiological ranges and 
Fig. 7. Infarct size measured in each group. Groups S, H and HS 
showed smaller infarct size than group I. There was no difference 
between infarct size of groups S, H and HS. P < 0.05 is remarked as 
follows: * vs. group I.466 www.ekja.org
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was not enough to affect the pH of the perfusate [27], and was a 
concentration used in previous studies [7,8,11].
We administered 18.5 μM H2S for 15 minutes prior to ischemia 
and found that it has a myocardial protective effect similar to 
sevoflurane; the infarct size in group H significantly reduced 
compared with group I. The reduction of infarct size was similar 
between the H2S and sevoflurane pretreatment. LVESP was 
higher in group H than in group I, HR was lower in group H 
than in group S, but dP/dtmax progressively decreased in later 
reperfusion periods. As in previous studies [9,10], H2S produced 
myocardial protective effects against ischemia and reperfusion 
injury in terms of hemodynamic aspects as well as reduced 
infarct size.
Our study sought to elucidate the cardioprotection of a com-
bined treatment of inhalation anesthetics with known pharma-
cological preconditioning activity, and H2S which protects 
against myocardial ischemia and reperfusion. In the case of H2S, 
a mechanism similar to PKC translocation and ATP-sensitive 
potassium channel activation induced by inhalation anesthetics 
has been suggested. However, H2S induces the translocation 
of different PKC subtypes [11] and suppresses cytochrome 
c oxidase, which will lead to the suspended animation-
like phenomenon which indicates a status of extremely low 
metabolic rate followed by a reduction in core body temperature 
[13,14]. Moreover, some studies cast doubt on H2S involvement 
in PKC translocation [25]. For these reasons, we expected good 
outcomes from the combined treatment with the inhalation 
anesthetic and H2S-induced suspended animation-like state. 
However, while the combined treatment reduced ischemia size, 
the results did not differ from those when each agent was used 
alone. Moreover, the combined treatment caused profound 
functional depression and showed no further hemodynamic 
benefits even though we used the minimum cardioprotective 
dose of each agent. In CEFR, although sevoflurane alone 
maintained a higher flow rate, the addition of H2S caused the 
rate to drop to group I levels. Generally, volatile anesthetics 
vasodilate coronary arteries by activation of endothelium 
KATP channels and promote endothelial NO release [18]. Also, 
H2S has a vasodilation effect; this effect is not related to KATP 
channels activation, and the endogenous production of NO 
inhibits the vasodilatory effect of H2S in coronary arteries [28]. 
Concerning CEFR, Geng et al. [15] reported that the effect of 
CEFR of H2S is dependent on the concentration of H2S. NaHS in 
a concentration of 100 μM did not affect the CEFR, but a higher 
concentration of NaHS inhibited CEFR in addition to a severe 
negative inotropic effect. These findings suggest that combined 
treatment with inhalation anesthetic and H2S could have an 
adverse effect on CEFR and our experimental results support 
this effect.
However, it cannot be assumed that this completely rules out 
any possible additional benefits from the combined treatment. 
First, further studies are needed to ascertain whether H2S-
induced metabolic suppression leads to temporary myocardial 
dysfunction. In order to determine this, we should examine 
metabolism in the control myocardium, each agent separately, 
as well as in combined treatment. Additionally, in in vivo 
experiments, we should look for early preconditioning effects 
after 60 minutes of reperfusion and late preconditioning 
effects 2-3 days after ischemia. In our research, combined 
treatment with sevoflurane and H2S led to no additional benefit 
compared to a single treatment with sevoflurane or H2S as an 
early preconditioning effect. Second, there is a possibility that 
a rate-limiting factor and a ceiling effect of cardioprotection 
exists in pharmacological preconditioning. Sevoflurane-
induced cardioprotection against ischemia and reperfusion 
continues to increase as concentrations increase, but only up 
to 1.6% [22]. NaHS administered between the preischemic 
state and late reperfusion state in doses of 0.1 μM and 1 μM 
showed a progressive decrease in ischemia size, but at 10 μM 
this effect did not occur [9]. Based on these results, including 
those of our study, more research is needed to determine what 
happens in the interaction between sevoflurane and naturally 
occurring H2S, considering its role as a gasotransmitter and a 
pharmacological preconditioner that reduces ischemia size.
In conclusion, we observed that H2S administered to isolated 
rat hearts had preconditioning effects against ischemia and 
reperfusion injury, such as faster systolic pressure recovery 
and reduction of infarct size. Sevoflurane was found to have 
preconditioning effects, as reported previously. Combination 
treatment with H2S and sevoflurane has an effect on infarct size 
reduction but caused a greater loss of hemodynamic function 
than a single treatment with H2S or sevoflurane for each 
substance.
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